Drugs / IMM-6-415
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06208124 | Feb 2024 → Apr 2025 | cutaneous melanoma, non-small cell lung carcinoma, pancreatic adenocarcinoma | Immuneering Corporation | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMM-6-415 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06208124 ↗ |
| Route | Oral | “Twice daily, oral tablet administered” NCT06208124 ↗ |